|
Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein Clinical research trials and Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein. Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein clinical trial. Participants oftentimes recieve the finest healthcare available for their Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein
Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein
For Condition: Ovarian Neoplasm
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Patients with measurable recurrent disease are treated on Regimen A; those with minimal residual disease are treated on Regimen B. Regimen A: Gene Therapy/Biological Response Modifier Therapy. Peripheral blood lymphocytes (PBL) stimulated with OKT3 (anti-CD3) monoclonal antibody and retrovirally transduced with the anti-ovarian cancer MOv-gamma chimeric receptor gene (MOv-PBL); with Interleukin-2 (Chiron), IL-2, NSC-373364. Intravenous administration. Regimen B: Gene Therapy/Biological Response Modifier Therapy. MOv-PBL; with IL-2. Peritoneal administration.
Details: Patients with recurrent, evaluable ovarian cancer will receive intravenous therapy with autologous peripheral blood lymphocytes that have been genetically modified to recognize an ovarian cancer-associated antigen (MOv-PBL). The duration of survival in the systemic circulation and at the tumor site will be evaluated. Patients will also be evaluated for a clinical response.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: INCLUSION CRITERIA Patients must have a biopsy-proven recurrent, resected recurrent, or residual epithelial ovarian cancer that has recurred following standard effective therapy including cisplatin/carboplatin or paclitaxel containing regimens. Age greater than or equal to 18 years. Clinical performance status of ECOG 0 or 1. Serum creatinine less than or equal to 2.0 mg/dl. Prior to infusion of MOv-PBL, more than 2 weeks must have elapsed since any prior therapy, besides surgical debulking. Women of child bearing potential must have a negative pregnancy test. Patients must have tumor that is positive on immunohistochemistry or FACS analysis for MOv18. Hgb greater than 9.0, WBC greater than 3000, and platelets greater than 100,000. Bilirubin 2.0 mg/dl or less and LFTs less than 3 times the upper limit of normal. FEV1 greater than 70% and DLCO greater than 70% predicted. Have an intact immune system, evidenced by a positive reaction to Candida Albicans skin tests, mumps skin test, or tetanus toxoid skin test on a standard anergy panel. EXCLUSION CRITERIA Require steroid therapy Are seropositive for HIV antibody. Are seropositive for hepatitis B antigen. Have active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular or respiratory systems are not eligible.
Total Enrollment: 50
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960011; 96-C-0011
Study Start Date: November 6, 1995
Record last reviewed: October 1, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001494
Other Ovarian Neoplasm Studies:
1. Phase II CT-2103/Carboplatin in Ovarian Cancer
2. A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)
3. Microarray Analysis for Human Genetic Disease
4. A Safety and Tolerability Study of Oral TAK-165 Administered to Subjects with Tumors Known to Express HER2
5. p53 Vaccine for Ovarian Cancer
Related Studies:
Other Ovarian Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Treatment of Patients with Advanced Epithelial Ovarian Cancer using Anti-CD3 Stimulated Peripheral Blood Lymphocytes Transduced with a Gene Encoding a Chimeric T-Cell Receptor Reactive with Folate Binding Protein
|
|
|
|
|
|
|
|